FineMark National Bank & Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

FineMark National Bank & Trust’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-570	Closed	-$9K	–	1164
2016 Q4	$9K	Hold	570	–	–	﹤0.01%	986
2016 Q3	$10K	Sell	570 -370	-39%	-$7.23K	﹤0.01%	956
2016 Q2	$15K	Buy	940 +570	+154%	+$9.22K	﹤0.01%	878
2016 Q1	$6K	Hold	370	–	–	﹤0.01%	1024
2015 Q4	$8K	Hold	370	–	–	﹤0.01%	984
2015 Q3	$7K	Buy	+370	New	+$11.7K	﹤0.01%	1049

Other funds holding HZNP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FineMark National Bank & Trust's HZNP Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2017, closing a stake of 570 shares — an estimated $9K sold.

FineMark National Bank & Trust first reported a position in HZNP in Q3 2015 and held it in 6 quarters. The position peaked at $15K in Q2 2016. 210 funds tracked by Wall St. Rank hold HZNP as of Q1 2017.

FineMark National Bank & Trust reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 570 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2017, an estimated $9K.
FineMark National Bank & Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 6 quarters.
FineMark National Bank & Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $15K in Q2 2016.
210 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.